EMA Opens Registration for European Network of Paediatric Research Workshop

News
Article

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

The European Medicines Agency (EMA) has begun registration for its sixth workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). The workshop will take place at EMA’s headquarters in London on June 26-27, 2014. The workshop, which aims to strengthen communication between stakeholders, will update participants from all aspects of the industry on “Enpr-EMA’s efforts to foster high-quality paediatric drug research and to contribute to the ongoing development of research and clinical trials in the area of paediatric medicine.”

Enpr-EMA, which is comprised by a network of research networks, investigators, and centers with expertise in performing clinical studies in children, fosters ethical research on the quality, safety and efficacy of medicines for use in children; helps recruit patients for clinical trials, and creates collaboration between networks.

Workshop registration forms can be found on EMA’s website) and should be submitted to enprema@ema.europa.eu.

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.